Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Pariser

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
The Journal of Investigative Dermatology|April 21, 2020
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled TrialSeth B Forman, David M Pariser, Yves Poulin, et al.
Current Medical Research and Opinion|November 29, 2019
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)David M Pariser, Eric L Simpson, Abhijit Gadkari, et al.
Dermatology and Therapy|May 19, 2022
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)Jerry Bagel, Tien Q Nguyen, Hermenio Lima, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.
Journal of Dermatological Science|January 23, 2023
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S studyAndrew Blauvelt, David M Pariser, Stephen Tyring, et al.
Archives of Dermatology|February 21, 2007
National Psoriasis Foundation clinical consensus on disease severityDavid M Pariser, Jerry Bagel, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|January 31, 2006
Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trialDiane Thiboutot, David M Pariser, Nancy Egan, et al.
The Journal of Clinical and Aesthetic Dermatology|January 3, 2022
Photodynamic Therapy with 5-aminolevulinic Acid 10% Gel and Red Light for the Treatment of Actinic Keratosis, Nonmelanoma Skin Cancers, and Acne: Current Evidence and Best PracticesNathalie C Zeitouni, Neal Bhatia, Roger I Ceilley, et al.
American Journal of Clinical Dermatology|October 21, 2021
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination DrugLinda Stein Gold, Hilary Baldwin, Leon H Kircik, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
The Journal of Investigative Dermatology|April 21, 2020
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled TrialSeth B Forman, David M Pariser, Yves Poulin, et al.
Current Medical Research and Opinion|November 29, 2019
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)David M Pariser, Eric L Simpson, Abhijit Gadkari, et al.
Dermatology and Therapy|May 19, 2022
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)Jerry Bagel, Tien Q Nguyen, Hermenio Lima, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.
Journal of Dermatological Science|January 23, 2023
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S studyAndrew Blauvelt, David M Pariser, Stephen Tyring, et al.
Archives of Dermatology|February 21, 2007
National Psoriasis Foundation clinical consensus on disease severityDavid M Pariser, Jerry Bagel, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|January 31, 2006
Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trialDiane Thiboutot, David M Pariser, Nancy Egan, et al.
The Journal of Clinical and Aesthetic Dermatology|January 3, 2022
Photodynamic Therapy with 5-aminolevulinic Acid 10% Gel and Red Light for the Treatment of Actinic Keratosis, Nonmelanoma Skin Cancers, and Acne: Current Evidence and Best PracticesNathalie C Zeitouni, Neal Bhatia, Roger I Ceilley, et al.
American Journal of Clinical Dermatology|October 21, 2021
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination DrugLinda Stein Gold, Hilary Baldwin, Leon H Kircik, et al.
Pageof 12